NEWS - Nov 10, 2022 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Read more
NEWS - Nov 8, 2022 Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 Read more
NEWS - Oct 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder Read more
NEWS - Sep 20, 2022 Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder Read more
NEWS - Aug 11, 2022 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Read more
NEWS - Aug 9, 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder Read more
NEWS - Aug 5, 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 Read more
NEWS - Jul 21, 2022 Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial Read more
NEWS - Jun 7, 2022 Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference Read more
NEWS - Jun 2, 2022 Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference Read more
